Endocrine Abstracts

In Graves' disease (GD), it is recognised that isolation of the rare pathogenic autoantibodies that stimulate the thyrotropin receptor (TSHR) would assist in understanding disease pathogenesis. To date, monoclonal antibodies (mabs) to the TSHR with thyroid stimulating activity (TSAbs) have been isolated from experimental models of GD which are 100 fold weaker than the reported single human mab with strong TSAb activity. We describe two novel IgG mabs from a murine model of GD ...

Introduction and Aims: Graves’ disease (GD) is mediated by thyroid stimulating antibodies (TSAbs) to the TSH receptor (TSHR). Treatments for GD have remained unchanged for more than 40 years with less than 50% of patients achieving long term remission with medical therapy. Experimental animal models have been described which facilitate understanding of disease mechanisms and permit studies of novel immunotherapeutic interventions. However studies aiming to perturb the Th1...

Study objective: We investigated the effect of linsitinib, a dual small-molecule kinase inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and the Insulin receptor (IR), on Graves’ Disease and thyroid eye disease. Graves‘ disease (GD), also known as ‘Basedow’s disease‘, is the most common cause for hyperthyroidism, typically presenting in patients between 40-60 years. GD is an autoimmune condition of the thyroid which is caused by autoanti...